Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC
October 10th 2023Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.
Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
September 28th 2023Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.
Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage
August 28th 2023Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.
TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer
August 24th 2023Alessandro Santin, MD, discusses the rationale and design of a phase 2 trial of sacituzumab govitecan in patients with persistent or recurrent endometrial cancer; unmet needs for patients with this disease; and key findings from the stage 1 portion of the trial.
Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer
August 10th 2023Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
Dr Cecchini on the Results of the PROSPECT Trial in Rectal Cancer
August 9th 2023Michael Cecchini, MD, discusses the phase 3 PROSPECT trial of neoadjuvant chemoradiation vs neoadjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with selective use of chemoradiation, followed by total mesorectal excision in patients with locally advanced rectal cancer, and how this regimen may fit into the current treatment landscape for rectal cancer.
PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials
Pamela Kunz, MD, details key clinical trial updates across the gastrointestinal cancer arena presented during the 2023 ASCO Annual Meeting, including the phase 3 PROSPECT trial in locally advanced rectal cancer and the phase 3 IMbrave050 trial in patients with resected in hepatocellular carcinoma at high risk of recurrence.
Dr Goldberg on the Investigation of VIC-1911 With/Without Sotorasib in KRAS G12C-Mutant NSCLC
July 21st 2023Sarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.
Dr Nassar on Treatment Options After Chemoradiation in Unresectable, Stage III, EGFR-Mutated NSCLC
June 20th 2023Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.
Adjuvant Osimertinib Provides OS Benefit in EGFR+ Stage IB-IIIA NSCLC
Treatment with adjuvant osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with resected, EGFR-mutated, stage IB to IIIA non–small cell lung cancer.
Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCC
April 10th 2023David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.
FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
March 9th 2023Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.
Adjuvant Osimertinib Elicits OS Improvement in Early-Stage EGFR-Mutated NSCLC
Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.